The introduction of Retatrutide ZPHC, at a dosage of 120mg, is creating considerable interest within the healthcare community. This innovative dual GIP and GLP-1 target medication seems to deliver significant improvements in weight loss compared to existing therapies. Initial patient data have demonstrated substantial declines in weight , possibly